SG10201913587WA - Inhibitors of receptor-interacting protein kinase 1 - Google Patents
Inhibitors of receptor-interacting protein kinase 1Info
- Publication number
- SG10201913587WA SG10201913587WA SG10201913587WA SG10201913587WA SG10201913587WA SG 10201913587W A SG10201913587W A SG 10201913587WA SG 10201913587W A SG10201913587W A SG 10201913587WA SG 10201913587W A SG10201913587W A SG 10201913587WA SG 10201913587W A SG10201913587W A SG 10201913587WA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- receptor
- protein kinase
- interacting protein
- interacting
- Prior art date
Links
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662292202P | 2016-02-05 | 2016-02-05 | |
US201662341019P | 2016-05-24 | 2016-05-24 | |
US201662363775P | 2016-07-18 | 2016-07-18 | |
US201662385217P | 2016-09-08 | 2016-09-08 | |
US201662417219P | 2016-11-03 | 2016-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913587WA true SG10201913587WA (en) | 2020-02-27 |
Family
ID=58054535
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806302RA SG11201806302RA (en) | 2016-02-05 | 2017-02-03 | Inhibitors of receptor-interacting protein kinase 1 |
SG10201913587WA SG10201913587WA (en) | 2016-02-05 | 2017-02-03 | Inhibitors of receptor-interacting protein kinase 1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806302RA SG11201806302RA (en) | 2016-02-05 | 2017-02-03 | Inhibitors of receptor-interacting protein kinase 1 |
Country Status (23)
Country | Link |
---|---|
US (6) | US9815850B2 (es) |
EP (1) | EP3414239A2 (es) |
JP (2) | JP6974331B2 (es) |
KR (1) | KR20180114910A (es) |
CN (2) | CN109071504B (es) |
AU (1) | AU2017213628B2 (es) |
CA (1) | CA3012832A1 (es) |
CL (1) | CL2018002081A1 (es) |
CO (1) | CO2018008707A2 (es) |
CR (1) | CR20180413A (es) |
DO (1) | DOP2018000175A (es) |
EA (1) | EA201891620A1 (es) |
EC (1) | ECSP18066138A (es) |
IL (2) | IL287136B2 (es) |
MA (1) | MA44007A (es) |
MX (3) | MX2018009448A (es) |
MY (1) | MY196648A (es) |
PH (1) | PH12018501583A1 (es) |
SA (1) | SA518392146B1 (es) |
SG (2) | SG11201806302RA (es) |
TN (1) | TN2018000276A1 (es) |
TW (1) | TWI781920B (es) |
WO (1) | WO2017136727A2 (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
RU2738232C2 (ru) | 2015-07-22 | 2020-12-09 | Энанта Фармасьютикалс, Инк. | Производные бензодиазепина как ингибиторы rsv |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
MY196648A (en) * | 2016-02-05 | 2023-04-27 | Denali Therapeutics Inc | Inhibitors of Receptor-Interacting Protein Kinase 1 |
TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
UA126231C2 (uk) | 2016-06-16 | 2022-09-07 | Деналі Терапьютікс Інк. | Піримідин-2-іламіно-1н-піразоли як інгібітори lrrk2 для застосування при лікуванні нейродегенеративних захворювань |
EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
JP6890179B2 (ja) | 2016-12-02 | 2021-06-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二環式アミド化合物及びその使用方法 |
US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
US11098058B2 (en) | 2017-07-14 | 2021-08-24 | Genentech, Inc. | Bicyclic ketone compounds and methods of use thereof |
CN107759574B (zh) * | 2017-08-29 | 2020-07-03 | 南京药石科技股份有限公司 | 一种5-氟-1h-吡唑-3-甲酸酯中间体及其合成方法 |
CN111386118B (zh) | 2017-09-29 | 2023-05-09 | 英安塔制药有限公司 | 作为rsv抑制剂的组合药物剂 |
BR112020007067A2 (pt) | 2017-10-11 | 2020-10-06 | F. Hoffmann-La Roche Ag | compostos bicíclicos para uso como inibidores rip1 quinase |
JP2021501183A (ja) | 2017-10-31 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二環式のスルホン及びスルホキシド、並びにその使用方法 |
MX2020004917A (es) | 2017-11-13 | 2020-08-06 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona. |
US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
WO2019199908A1 (en) | 2018-04-11 | 2019-10-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
EP3781571B1 (en) * | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
MD3788044T2 (ro) | 2018-05-03 | 2023-12-31 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
AU2019262142A1 (en) | 2018-05-03 | 2020-11-26 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
US20210292340A1 (en) * | 2018-06-26 | 2021-09-23 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
WO2020044206A1 (en) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors for use in the treatment cancer |
WO2020054670A1 (ja) * | 2018-09-10 | 2020-03-19 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
JP7045526B2 (ja) * | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Rip1キナーゼを阻害する複素環状アミド及びその使用 |
CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
WO2020151589A1 (zh) * | 2019-01-25 | 2020-07-30 | 北京赛特明强医药科技有限公司 | 酰胺基桥连杂环类化合物、及其组合物与应用 |
SG11202110137VA (en) | 2019-03-18 | 2021-10-28 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
WO2020210246A1 (en) | 2019-04-09 | 2020-10-15 | Enanta Pharmaceuticals, Inc, | Heterocyclic compounds as rsv inhibitors |
CN114008038B (zh) * | 2019-05-31 | 2023-01-24 | 南京明德新药研发有限公司 | 作为rip-1激酶抑制剂的双并环类化合物及其应用 |
CN110172068A (zh) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用 |
US20210040115A1 (en) * | 2019-08-09 | 2021-02-11 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds as ripk1 inhibitors |
US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
CR20220075A (es) | 2019-09-06 | 2022-07-14 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos |
JP7443495B2 (ja) | 2019-09-06 | 2024-03-05 | ライジェル ファーマシューティカルズ, インコーポレイテッド | ヘテロ環式rip1キナーゼ阻害剤 |
WO2021050672A1 (en) * | 2019-09-11 | 2021-03-18 | Ohio State Innovation Foundation | Kinase inhibitors for the treatment of neurodegenerative diseases |
MX2022003671A (es) | 2019-09-27 | 2022-04-25 | Univ Texas | Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades. |
KR20220101083A (ko) | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스 헤테로사이클릭 화합물 |
US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
MX2022005509A (es) | 2019-11-07 | 2022-10-18 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 heterociclicos. |
JP2023502514A (ja) * | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤 |
UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
CN115397431A (zh) * | 2020-04-17 | 2022-11-25 | 建新公司 | 用于治疗涉及全身过度炎症反应的病症的eclitasertib |
TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ripk1抑制劑之異㗁唑啶及其用途 |
AR122703A1 (es) * | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
CN114716427B (zh) * | 2021-01-07 | 2024-04-26 | 成都贝诺科成生物科技有限公司 | 一种作为rip抑制剂的化合物及其制备方法和用途 |
WO2022171110A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof |
WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
KR20230161976A (ko) | 2021-02-26 | 2023-11-28 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스성 헤테로사이클릭 화합물 |
TW202300490A (zh) * | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
JP2022165218A (ja) | 2021-04-19 | 2022-10-31 | 住友ゴム工業株式会社 | ゴム組成物及びタイヤ |
CN114989156A (zh) * | 2021-05-19 | 2022-09-02 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
JP7406672B2 (ja) | 2021-08-10 | 2023-12-27 | アッヴィ・インコーポレイテッド | ニコチンアミド系ripk1阻害剤 |
WO2023043284A1 (en) * | 2021-09-17 | 2023-03-23 | Bisichem Co., Ltd. | Fused heterocyclic rings as ripk1 inhibitors |
TW202340182A (zh) | 2021-11-11 | 2023-10-16 | 美商健臻公司 | 做為ripk1抑制劑之異㗁唑啶及其用途 |
WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
KR20230100646A (ko) | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
EP4209213A1 (en) | 2022-01-05 | 2023-07-12 | Universität zu Köln | Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases |
WO2023137007A1 (en) * | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型 |
CN117849327A (zh) * | 2024-03-06 | 2024-04-09 | 军科正源(北京)药物研究有限责任公司 | 用于检测苏金单抗抗药性抗体的方法 |
Family Cites Families (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US4477464A (en) | 1983-02-10 | 1984-10-16 | Ciba-Geigy Corporation | Hetero-benzazepine derivatives and their pharmaceutical use |
EP0187037A3 (en) | 1984-12-21 | 1988-03-23 | Takeda Chemical Industries, Ltd. | Piperidine derivatives, their production and use |
EP0322779A3 (en) | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
JPH0334977A (ja) | 1989-06-29 | 1991-02-14 | Yoshitomi Pharmaceut Ind Ltd | イミダゾリルベンゾラクタム化合物 |
IL98526A0 (en) | 1990-06-18 | 1992-07-15 | Merck & Co Inc | Pyridones,processes for their preparation and pharmaceutical compositions containing them |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
US5206235A (en) | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
CA2078758C (en) | 1991-09-27 | 2003-12-09 | Alan M. Warshawsky | 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
US5457196A (en) | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
JP3358069B2 (ja) | 1991-12-24 | 2002-12-16 | 武田薬品工業株式会社 | 三環性複素環類、その製造法及び剤 |
US5484917A (en) | 1993-06-16 | 1996-01-16 | Pfizer Inc. | Substituted tetrahydrobenzazepinones |
CA2139417A1 (en) | 1992-07-01 | 1994-01-20 | Arthur A. Nagel | Benzothiazepine and benzoxazepine derivatives |
NZ254656A (en) | 1992-08-24 | 1995-12-21 | Merrell Dow Pharma | Tricyclic benzazepine derivatives; preparation and pharmaceutical compositions |
US5420271A (en) | 1992-08-24 | 1995-05-30 | Merrell Dow Pharmaceuticals, Inc. | 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase |
US5283241A (en) | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
SK65094A3 (en) | 1992-09-03 | 1995-03-08 | Boehringer Ingelheim Kg | Aminoacid derivatives, process for producing the same and pharmaceutical compositions containing these derivatives |
US5583130A (en) | 1992-09-25 | 1996-12-10 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5317017A (en) | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
US5374721A (en) | 1992-10-14 | 1994-12-20 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
DE69332946T2 (de) | 1992-10-16 | 2004-05-19 | Suprex Corp. | Automatisierte extrakion mittels eines superkritischen fluidum |
GB2272439A (en) | 1992-11-13 | 1994-05-18 | Merck & Co Inc | Benzo-fused lactams that inhibit the release of growth hormone |
US5284841A (en) | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
GB9307833D0 (en) | 1993-04-15 | 1993-06-02 | Glaxo Inc | Modulators of cholecystokinin and gastrin |
EP0703222A1 (en) | 1993-05-13 | 1996-03-27 | Yoshitomi Pharmaceutical Industries, Ltd. | 3-aminoazepine compound and pharmaceutical use thereof |
US5430144A (en) | 1993-07-26 | 1995-07-04 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
US5606054A (en) | 1993-12-14 | 1997-02-25 | Merck & Co., Inc. | Heterocyclic-fused lactams promote release of growth hormone |
EP0756602B1 (en) | 1994-04-14 | 1999-06-30 | Glaxo Wellcome Inc. | Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines |
CZ325496A3 (en) | 1994-05-07 | 1997-09-17 | Boehringer Ingelheim Kg | Amino acid derivatives, process for preparing and pharmaceutical compositions containing thereof |
IL114955A (en) | 1994-08-17 | 1999-12-22 | Novo Nordisk As | N-substituted naphthofused lactams and pharmaceutical compositions containing them |
GB9420748D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | 1,5 benzodiazepine derivatives |
GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
GB9420747D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | 1,5 benzodiazepine derivatives |
MX9703615A (es) | 1994-11-17 | 1997-08-30 | Ciba Sc Holding Ag | Monomeros reticulables y composicion, asi como polimeros reticulados. |
US5587375A (en) | 1995-02-17 | 1996-12-24 | Bristol-Myers Squibb Company | Azepinone compounds useful in the inhibition of ACE and NEP |
US5726171A (en) | 1995-06-07 | 1998-03-10 | Merck & Co Inc | N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides |
US5700797A (en) | 1995-06-07 | 1997-12-23 | Merck & Co, Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
JPH11506760A (ja) | 1995-06-07 | 1999-06-15 | メルク エンド カンパニー インコーポレーテッド | 新規なn−(2,4−ジオキソ−2,3,4,5−テトラヒドロ−1h−1,5−ベンゾジアゼピン−3イル)−3−アミド |
US5691331A (en) | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
SK282222B6 (sk) | 1995-09-15 | 2001-12-03 | Sanofi-Synthelabo | Deriváty 2(1h)-chinolónu, spôsob ich prípravy a ich použitie ako liečiv |
EP0900791A1 (en) | 1995-12-27 | 1999-03-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
US5747235A (en) | 1996-01-26 | 1998-05-05 | Eastman Kodak Company | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity |
JPH09295996A (ja) | 1996-03-06 | 1997-11-18 | Takeda Chem Ind Ltd | システインプロテアーゼ阻害化合物 |
ATE241600T1 (de) | 1996-06-29 | 2003-06-15 | Samjin Pharm Co Ltd | Piperazin-derivate und verfahren zu ihrer herstellung |
DE19638020A1 (de) | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
CA2274250A1 (en) | 1996-12-06 | 1998-06-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1.beta. converting enzyme |
JPH10251295A (ja) | 1997-03-07 | 1998-09-22 | Ono Pharmaceut Co Ltd | テトラゾール誘導体 |
JP2001515842A (ja) | 1997-08-11 | 2001-09-25 | シーオーアール セラピューティクス インコーポレイテッド | 選択的Xa因子阻害剤 |
US6211174B1 (en) | 1997-10-31 | 2001-04-03 | Merck & Co., Inc. | Naphtho-fused lactams promote release of growth hormone |
FR2781483A1 (fr) | 1998-07-21 | 2000-01-28 | Hoechst Marion Roussel Inc | Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant |
DE19858253A1 (de) | 1998-12-17 | 2000-06-21 | Aventis Pharma Gmbh | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden |
JP2000256318A (ja) | 1999-03-02 | 2000-09-19 | Toa Eiyo Ltd | 縮合複素環誘導体、その製造法およびそれを含有する医薬品 |
FR2803594B1 (fr) | 2000-01-11 | 2002-07-19 | Centre Nat Rech Scient | Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations |
WO2001074784A1 (en) | 2000-04-03 | 2001-10-11 | Dupont Pharmaceuticals Company | CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION |
CA2404023A1 (en) | 2000-04-03 | 2001-10-11 | Richard E. Olson | Cyclic lactams as inhibitors of a.beta. protein production |
AU2001255408A1 (en) | 2000-04-14 | 2001-10-30 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
SK15592002A3 (sk) | 2000-04-24 | 2003-04-01 | Vertex Pharmaceuticals Incorporated | Spôsob a medziprodukty na prípravu substituovaných acetálov kyseliny aspartovej |
GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
CN1386118A (zh) | 2000-06-01 | 2002-12-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物 |
AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
WO2002020500A2 (en) | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
US7294457B2 (en) | 2001-08-07 | 2007-11-13 | Boehringer Ingelheim (Canada) Ltd. | Direct binding assay for identifying inhibitors of HCV polymerase |
WO2003031376A1 (en) | 2001-10-12 | 2003-04-17 | Aventis Pharmaceuticals Inc. | Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
AU2003247772A1 (en) * | 2002-06-27 | 2004-01-19 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
US7208487B2 (en) | 2002-12-13 | 2007-04-24 | Cytokinetics, Incorporated | Compounds, compositions and methods |
CA2518830A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
JP2005035933A (ja) | 2003-07-15 | 2005-02-10 | Takeda Chem Ind Ltd | 含窒素縮合複素環化合物の製造方法 |
DK2384753T3 (en) | 2003-08-29 | 2016-04-11 | Brigham & Womens Hospital | Hydantoin derivatives as inhibitors of cell necrosis |
JP2007532474A (ja) | 2003-10-10 | 2007-11-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にhcvのns3−ns4aプロテアーゼの阻害剤 |
US20050256056A1 (en) | 2003-12-05 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer University Of California | Peptide inhibitors of HIV |
US20070010428A1 (en) | 2004-09-03 | 2007-01-11 | Mcmurray John S | Inhibitors of signal transduction and activator of transcription 3 |
US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
MX2007004393A (es) * | 2004-10-13 | 2007-04-25 | Merck & Co Inc | Antagonistas del receptor a peptido relacionado con el gen calcitonina. |
CA2583534A1 (en) * | 2004-10-14 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
WO2006059164A2 (en) | 2004-12-02 | 2006-06-08 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amides |
US7875627B2 (en) | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
WO2006071775A2 (en) | 2004-12-29 | 2006-07-06 | Elan Pharmaceuticals, Inc. | Novel compounds useful for bradykinin b1 receptor antagonism |
WO2006079077A2 (en) | 2005-01-20 | 2006-07-27 | Acadia Pharmaceuticals Inc. | Use of diltiazem or analogs thereof as modulators of ghrelin receptor |
US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
AP2007004160A0 (en) | 2005-04-01 | 2007-10-31 | Warner Lambert Co | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
US20080176830A1 (en) | 2005-04-14 | 2008-07-24 | Adams Nicholas D | Compounds, Compositions, and Methods |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US20090240055A1 (en) | 2005-09-23 | 2009-09-24 | Krepski Larry R | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof |
CA2632476A1 (en) | 2005-12-05 | 2007-06-14 | Affinium Pharmaceuticals, Inc. | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
WO2007126871A1 (en) | 2006-03-29 | 2007-11-08 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
WO2007145922A2 (en) | 2006-06-09 | 2007-12-21 | Merck & Co., Inc. | Benzazepinones as sodium channel blockers |
US8318720B2 (en) | 2006-07-20 | 2012-11-27 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as Fab I inhibitors |
JP5511379B2 (ja) | 2006-07-21 | 2014-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cgrpレセプターアンタゴニスト |
WO2008040778A2 (en) | 2006-10-04 | 2008-04-10 | Tibotec Pharmaceuticals Ltd. | Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c |
CL2007002904A1 (es) * | 2006-10-10 | 2008-06-06 | Amgen Inc Soc Organizada Bajo | Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras. |
EP1939187A1 (en) * | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
WO2008080056A2 (en) | 2006-12-21 | 2008-07-03 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
US20100144715A1 (en) | 2007-02-28 | 2010-06-10 | Hoyt Scott B | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers |
WO2008135525A2 (en) | 2007-05-02 | 2008-11-13 | Boehringer Ingelheim International Gmbh | Substituted azetidines, manufacturing and use thereof as medicaments |
EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES |
WO2009019115A1 (en) | 2007-08-03 | 2009-02-12 | Sanofi-Aventis | Caspase imaging probes |
WO2009085256A1 (en) | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
EP2090578A1 (en) | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
EP2085399A1 (en) | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
JP4708443B2 (ja) * | 2008-01-31 | 2011-06-22 | トヨタ自動車株式会社 | 作動制御マップおよび白線認識装置 |
CA2711367A1 (en) | 2008-02-19 | 2009-08-27 | Merck Sharp & Dohme Corp. | Imidazobenzazepine cgrp receptor antagonists |
WO2009103432A2 (en) | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
US20110104161A1 (en) | 2008-05-14 | 2011-05-05 | Burgess Teresa L | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
US7884074B2 (en) | 2008-05-15 | 2011-02-08 | Ikaria Development Subsidiary Two, LLC | Compounds and methods for prevention and/or treatment of inflammation using the same |
WO2010013794A1 (en) | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
US8088890B2 (en) | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
MX2011004018A (es) | 2008-10-14 | 2011-06-24 | Ning Xi | Compuestos y metodos de uso. |
AU2009333427A1 (en) | 2008-12-17 | 2011-07-28 | Merck Sharp & Dohme Corp. | Imidazolinone derivatives as CGRP receptor antagonists |
CN102548999A (zh) | 2009-01-20 | 2012-07-04 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
US8624063B2 (en) | 2009-06-30 | 2014-01-07 | Wisconsin Alumni Research Foundation | Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing |
JP2013505252A (ja) | 2009-09-16 | 2013-02-14 | サイリーン ファーマシューティカルズ インコーポレーティッド | 三環式タンパク質キナーゼ調節剤 |
AU2010319842A1 (en) | 2009-10-29 | 2012-05-17 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US20130137642A1 (en) | 2010-04-23 | 2013-05-30 | Demetrios Vavvas | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
EP2581373A4 (en) | 2010-05-11 | 2013-10-23 | 8337187 Canada Inc | BENZO OR PYRIDO IMIDAZOLE DERIVATIVE |
CA2799966A1 (en) | 2010-05-24 | 2011-12-01 | Vanderbilt University | Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators |
WO2012061408A2 (en) | 2010-11-02 | 2012-05-10 | Rigel Pharmaceuticals. Inc. | Method for making macrocycles |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
AU2012284091B2 (en) | 2011-07-19 | 2015-11-12 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013013826A1 (en) | 2011-07-27 | 2013-01-31 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract |
JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
WO2013059791A2 (en) | 2011-10-21 | 2013-04-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for promoting axon regeneration and nerve function |
SG11201402409UA (en) | 2011-12-02 | 2014-10-30 | Aurigene Discovery Tech Ltd | Substituted pyridine derivatives as fabi inhibitors |
US9062075B2 (en) | 2011-12-02 | 2015-06-23 | Aurigene Discovery Technologies Limited | Tetrahydropyridine derivatives as FabI inhibitors |
JP2015518504A (ja) | 2012-04-03 | 2015-07-02 | スリーエム イノベイティブ プロパティズ カンパニー | 光塩基発生剤を含む架橋性組成物 |
WO2013189241A1 (zh) | 2012-06-20 | 2013-12-27 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
TWI520962B (zh) | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
BR112015000649A2 (pt) | 2012-07-13 | 2017-06-27 | Hoffmann La Roche | compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção |
BR112015001830A2 (pt) | 2012-08-09 | 2017-07-04 | Hoffmann La Roche | composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção |
CN103664904A (zh) | 2012-09-07 | 2014-03-26 | 李振 | 一种γ-分泌酶抑制剂及其用途 |
WO2014072930A2 (en) | 2012-11-09 | 2014-05-15 | Aurigene Discovery Technologies Limited | Fused pyridine derivatives as antibacterial agents |
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
FR3003860B1 (fr) | 2013-03-29 | 2015-11-27 | Oreal | Composes derives d'iridoides proteges ou non, composition les comprenant, utilisation comme colorant des fibres keratiniques et dispositifs |
WO2014170892A1 (en) | 2013-04-15 | 2014-10-23 | Yeda Research And Development Co. Ltd. | Inhibition of rip kinases for treating lysosomal storage diseases |
WO2015027137A1 (en) | 2013-08-23 | 2015-02-26 | University Of Tennessee Research Foundation | Improved synthesis of capuramycin and its analogues |
WO2015103583A1 (en) | 2014-01-06 | 2015-07-09 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
WO2015104677A1 (en) | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
WO2015184257A2 (en) | 2014-05-30 | 2015-12-03 | Icahn School Of Medicine At Mount Sinai | Small molecule transcription modulators of bromodomains |
US9616047B2 (en) | 2014-06-30 | 2017-04-11 | Regents Of University Of Minnesota | Inhibitors of beta-catenin in treatment of colorectal cancer |
JP2017526670A (ja) | 2014-08-13 | 2017-09-14 | マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー.ファウ. | ネクロトーシス(necroptosis)の阻害による腫瘍転移の阻止 |
CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
CN107108512B (zh) | 2014-10-10 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
EP3017825A1 (en) | 2014-11-06 | 2016-05-11 | Ludwig-Maximilians-Universität München | An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same |
JP6772141B2 (ja) | 2014-12-24 | 2020-10-21 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ,ベイジン | ネクローシス阻害薬 |
CA2972294C (en) | 2014-12-24 | 2018-09-25 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
CN107001337B (zh) | 2015-01-13 | 2021-05-04 | 诺华股份有限公司 | 作为血管紧张素ii型拮抗剂的吡咯烷衍生物 |
JP2018505199A (ja) | 2015-02-13 | 2018-02-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | (S)−5−ベンジル−N−(5−メチル−4−オキソ−2,3,4,5テトラヒドロベンゾ[b][1,4]オキサゼピン−3−イル)−4H−1,2,4−トリアゾール−3−カルボキサミドの結晶形 |
TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
TWI763630B (zh) * | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
KR101858346B1 (ko) | 2015-07-07 | 2018-05-16 | 가톨릭대학교 산학협력단 | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
US10787462B2 (en) | 2015-10-23 | 2020-09-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
MY196648A (en) * | 2016-02-05 | 2023-04-27 | Denali Therapeutics Inc | Inhibitors of Receptor-Interacting Protein Kinase 1 |
-
2017
- 2017-02-03 MY MYPI2018702604A patent/MY196648A/en unknown
- 2017-02-03 SG SG11201806302RA patent/SG11201806302RA/en unknown
- 2017-02-03 CN CN201780021671.8A patent/CN109071504B/zh active Active
- 2017-02-03 KR KR1020187025396A patent/KR20180114910A/ko unknown
- 2017-02-03 JP JP2018541178A patent/JP6974331B2/ja active Active
- 2017-02-03 WO PCT/US2017/016509 patent/WO2017136727A2/en active Application Filing
- 2017-02-03 EP EP17705751.0A patent/EP3414239A2/en active Pending
- 2017-02-03 CN CN202210159353.0A patent/CN114437105A/zh active Pending
- 2017-02-03 MX MX2018009448A patent/MX2018009448A/es unknown
- 2017-02-03 CR CR20180413A patent/CR20180413A/es unknown
- 2017-02-03 US US15/424,216 patent/US9815850B2/en active Active
- 2017-02-03 TW TW106103687A patent/TWI781920B/zh active
- 2017-02-03 SG SG10201913587WA patent/SG10201913587WA/en unknown
- 2017-02-03 AU AU2017213628A patent/AU2017213628B2/en active Active
- 2017-02-03 TN TNP/2018/000276A patent/TN2018000276A1/en unknown
- 2017-02-03 EA EA201891620A patent/EA201891620A1/ru unknown
- 2017-02-03 IL IL287136A patent/IL287136B2/en unknown
- 2017-02-03 MA MA044007A patent/MA44007A/fr unknown
- 2017-02-03 CA CA3012832A patent/CA3012832A1/en active Pending
- 2017-09-29 US US15/721,470 patent/US10131676B2/en active Active
- 2017-09-29 US US15/721,419 patent/US9896458B2/en active Active
-
2018
- 2018-07-19 IL IL260674A patent/IL260674B/en unknown
- 2018-07-25 PH PH12018501583A patent/PH12018501583A1/en unknown
- 2018-08-01 DO DO2018000175A patent/DOP2018000175A/es unknown
- 2018-08-02 SA SA518392146A patent/SA518392146B1/ar unknown
- 2018-08-02 MX MX2021013228A patent/MX2021013228A/es unknown
- 2018-08-02 MX MX2021013226A patent/MX2021013226A/es unknown
- 2018-08-02 CL CL2018002081A patent/CL2018002081A1/es unknown
- 2018-08-21 CO CONC2018/0008707A patent/CO2018008707A2/es unknown
- 2018-09-03 EC ECSENADI201866138A patent/ECSP18066138A/es unknown
- 2018-09-13 US US16/130,817 patent/US10604535B2/en active Active
-
2020
- 2020-02-05 US US16/782,446 patent/US20200317691A1/en not_active Abandoned
-
2021
- 2021-02-25 US US17/185,684 patent/US20230043400A1/en not_active Abandoned
- 2021-11-02 JP JP2021179107A patent/JP7381543B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287136B1 (en) | Receptor inhibitors - interacting with protein kinase 1 | |
IL261472B (en) | Inhibitors of binding the wdr5 protein with other proteins | |
EP3177295A4 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
IL268614B (en) | Aminotriazolopyridines as kinase inhibitors | |
ZA201700786B (en) | Protein kinase c inhibitors and methods of their use | |
IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
ZA201808238B (en) | Certain protein kinase inhibitors | |
ZA202000107B (en) | Aminothiazole compounds as protein kinase inhibitors | |
EP3555092A4 (en) | PROTEIN KINASE INHIBITORS | |
EP3134390A4 (en) | Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides | |
ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
EP3134399A4 (en) | Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides | |
IL268771A (en) | Peptide kinase inhibitors and methods of using them | |
GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors |